${vImageAlt}

Spotlight on Dr. Jian Yang

Jian Yang's research program includes cancer research and anticancer drug development; novel bioremediation strategies and bioresource technologies; and novel antimicrobial hybrid drugs for infectious diseases.

Bio

Jian Yang is an associate professor and member of the Drug Discovery and Development Research Group. He obtained his Ph.D. in protein chemistry and crystallography at the University of Saskatchewan and conducted postdoctoral work in molecular medicine at the University of Massachusetts Medical School and basic medical science at Brandeis University. Jian teaches courses on pharmacotherapeutics, drug discovery and design, and pathophysiology and pharmacology. He is a co-founder and the inaugural president of the Saskatchewan Center for Science and Religion.

Research

Jian’s interdisplinary research program covers a broad range of topics, including cancer research and anticancer drug development; novel bioremediation strategies and bioresource technologies; and novel antimicrobial hybrid drugs for bovine respiratory disease, bovine mastitis and other infectious diseases.

Recent Publications

A.H. Kaoryo, J. Yang and L.D. Wilson, 2018. Dual function polymers for tandem adsorption and biodegradation of chlorophenols. Frontiers in Chemistry (Accepted)

S. Xiao and J. Yang, 2018. Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells. Investigational New Drugs

Y. Yang, J. Yang, J. Cao and Z. Wang, 2018. Pretreatment with concurrent UV photocatalysis and alkaline H2O2 enhanced the enzymatic hydrolysis of sisal waste. Bioresource Technology, 267, 517-523.

M.K. Sakharkar, K. Rajamanickam, R. Chandra, H.A. Khan, A.S. Alhomida and J. Yang, 2018. Identification of novel drug targets in bovine respiratory disease (BRD): an essential step in applying biotechnological techniques to develop more effective therapeutic treatments. Drug Design, Development and Therapy, 12, 1135-1146.

L. Chen, E.S. Krol, M.K. Sakharkar, H.A. Khan, A.S. Alhomida and J. Yang, 2017. Residues His172 and Lys238 are essential for the catalytic activity of the maleylacetate reductase from Sphingobium chlorophenolicum strain L-1. Scientific Reports, 7, Article ID 18097.

M. Mazumder, P. Ponnan, U. Das, S. Gourinath, H.A. Khan, J. Yang and M.K. Sakharkar, 2017. Investigations on binding pattern of kinase inhibitors with PPARg: molecular docking, molecular dynamics simulations, and free energy calculation studies. PPAR Research, 2017, Article ID 6397836.

B. Ling, D. Michel, M.K. Sakharkar and J. Yang, 2016. Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells. Drug Design, Development and Therapy, 10, 3563-3572.

 

Share this story